Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications Guidance for Industry
The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and efficacy of pharmaceutical products. One of its key responsibilities is monitoring post-market safety through pharmacoepidemiologic studies. The FDA’s guidance document, “Conducting and Reporting Pharmacoepidemiologic Safety Studies,” provides detailed recommendations on the design, conduct, and reporting of such studies. Overview […]
ANDA Submissions | Amendments to Abbreviated New Drug Applications Under GDUFA
The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and effectiveness of medical devices. One of its key regulatory requirements is the Medical Device Reporting (MDR) system, which mandates manufacturers to report adverse events and device malfunctions. The FDA’s guidance document, “Medical Device Reporting for Manufacturers,” provides clarity on […]
Electronic Submission Template for Medical Device De Novo Requests
The U.S. Food and Drug Administration (FDA) has released guidance on the importance of diversity in clinical trials to ensure that study populations reflect the demographics of the intended treatment population. The document, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials,” provides recommendations for sponsors to develop […]
Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA
The U.S. Food and Drug Administration (FDA) has issued guidance to enhance the transparency and consistency of benefit-risk assessments in the regulatory review process for new drug applications (NDAs) and biologics license applications (BLAs). The document, “Benefit-Risk Assessment for New Drug and Biologic Applications,” outlines how the FDA evaluates the therapeutic benefits and associated risks […]
FDA and Industry Procedures for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act
The U.S. Food and Drug Administration (FDA) provides detailed guidance on the nonclinical studies required to support Investigational New Drug (IND) applications. The document, “Nonclinical Safety Evaluation of Drug or Biologic Combinations,” outlines key recommendations for conducting preclinical studies that ensure the safety of investigational products before they proceed to human trials. This article highlights […]
Mammography Quality Standards Act and Regulation Amendments: Small Entity Compliance Guide
The U.S. Food and Drug Administration (FDA) continues to modernize regulatory processes by encouraging electronic submissions for Investigational New Drug (IND) applications. The FDA’s guidance document, “Electronic Submissions for IND Applications,” provides essential recommendations on transitioning from paper-based to electronic submissions, ensuring compliance with regulatory standards and improving efficiency. This article highlights key takeaways from […]
CVM GFI #63 (VICH GL1) Validation of Analytical Procedures: Definition and Terminology
The U.S. Food and Drug Administration (FDA) plays a critical role in overseeing the safety and efficacy of investigational drugs before they enter clinical trials. The FDA’s guidance document, “Investigational New Drug (IND) Applications,” provides essential recommendations for submitting IND applications, ensuring compliance with regulatory standards. This article highlights key takeaways from the guidance and […]
Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers
The U.S. Food and Drug Administration (FDA) continues to evolve its regulatory framework to incorporate advancements in digital health technologies (DHTs). The FDA’s guidance document, “Digital Health Technologies for Drug Development,” provides crucial recommendations for the use of digital tools in clinical trials and regulatory submissions. This article highlights key takeaways from the guidance and […]
Bioresearch Monitoring Technical Conformance Guide
The U.S. Food and Drug Administration (FDA) plays a pivotal role in establishing regulatory standards for drug development and approval. The FDA’s guidance document, “Clinical Trial Endpoints for Drug Development,” provides essential recommendations for selecting appropriate endpoints in clinical trials. This article highlights key takeaways from the guidance and its implications for pharmaceutical companies, researchers, […]